Seat No.: _____ Enrolment No.
_____________
GUJARAT TECHNOLOGICAL UNIVERSITY
Pharm D – 5th Year/Pharm.D(PB) -2nd Year • EXAMINATION – WINTER - 2023
Subject Code: 858803/828903 Date:16/01/2024
Subject Name: Clinical Pharmacokinetics & Pharmacotherapeutic Drug Monitoring
Time: 10:30 AM to 1:30 PM Total Marks: 70
Instructions:
1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.
Q.1 (a) Define: Clinical Pharmacokinetics. Explain all parameters that describe a 06
typical plasma level time curve.
(b) Describe the role of genetic polymorphism in drug targets. 04
(c) Explain the influence of drug interaction on drug absorption with examples. 04
Q.2 (a) Describe Bayesian theory and explain dosing with feedback in detail. 06
(b) Define Creatinine clearance. Enumerate various formulae used for the 04
measurement of Creatinine clearance.
(c) Explain role of genetics and disease condition in the individualization of drug 04
dosage regimen.
Q.3 (a) Explain the various factors considered in the design of dosage regimen for 06
geriatric and obese patients.
(b) Describe the protocol for TDM of a drug. What is the role of clinical 04
pharmacist in TDM?
(c) Write a note on importance and applications of Clinical Pharmacokinetics. 04
Q.4 (a) Enumerate various causes for renal impairment. Discuss in detail the 06
pharmacokinetic considerations in the renal failure patients.
(b) Explain the process and clinical significance of conversion from intravenous to 04
oral dosing.
(c) Explain the effect of inhibition of biliary excretion of drugs. Enlist the drug 04
interactions which influencing biliary excretion.
Q.5 (a) Discuss the importance of genetic polymorphism of Cytochrome P-450 06
isozymes on drug metabolism with suitable examples.
(b) Write a note on: Indications and functions of TDM process in detail. 04
(c) Discuss population pharmacokinetic analysis using NONMEM method. 04
Q. 6 (a) Explain the necessity and process of TDM in patients receiving Digoxin and 06
Carbamazepine.
(b) Explain the Giusti-Hayton method for the dosage adjustment in uremic patients. 04
(c) Explain the role of nomograms and tabulations in the design of dosage regimen. 04
Q.7 (a) Enlist various factors for hepatic impairment. Discuss in detail the 06
pharmacokinetic considerations in the hepatic disease patients.
(b) What are the factors considered in the design of dosage regimen for pediatric 04
patients? Give any two formulae for the calculation of child dose.
(c) Write a note on: Various methods of Extracorporeal removal of drugs. 04
***************
